Clinical Trial Aims to Lower Insulin Requirements


By: Rebecca Borlaug

Ergo Science Corporation, located in Charlestown, Massachusetts, has initiated a human clinical trial for FDA approval of its Ergoset tablets. The tablets are intended to reduce insulin requirements for people with type 2 diabetes who are on insulin.

The object of the trial is to lower BGs and daily insulin requirements of people with type 2 whose BGs have not been sufficiently controlled on oral hypoglycemic agents and insulin. This type of patient represents approximately three million of the seven million type 2s who receive treatment for their diabetes.

Efficient use of insulin for these patients is important as excess insulin in the bloodstream has been associated with cardiovascular disease.

The phase III human clinical trial of Ergoset for FDA approval demonstrated “significant and meaningful results in people with type 2 diabetes,” according to a company press release.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.